Shares of G1 Therapeutics Inc (NASDAQ:GTHX) have earned an average broker rating score of 1.25 (Strong Buy) from the four brokers that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a buy recommendation and three have assigned a strong buy recommendation to the company.

Brokerages have set a twelve-month consensus price objective of $29.67 for the company, according to Zacks. Zacks has also given G1 Therapeutics an industry rank of 106 out of 265 based on the ratings given to its competitors.

A number of analysts recently weighed in on the stock. Cowen and Company reaffirmed a “buy” rating on shares of G1 Therapeutics in a report on Wednesday, August 9th. Zacks Investment Research cut shares of G1 Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th.

G1 Therapeutics (NASDAQ GTHX) traded up 3.2649% on Monday, hitting $22.7699. 18,165 shares of the company traded hands. The stock’s 50-day moving average is $24.81 and its 200 day moving average is $19.00. The stock’s market cap is $644.05 million. G1 Therapeutics has a 12 month low of $12.04 and a 12 month high of $28.67.

G1 Therapeutics (NASDAQ:GTHX) last released its quarterly earnings data on Wednesday, August 9th. The company reported ($1.09) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.61) by ($0.48). Equities research analysts expect that G1 Therapeutics will post ($2.92) earnings per share for the current fiscal year.

Several large investors have recently bought and sold shares of the company. RA Capital Management LLC bought a new position in shares of G1 Therapeutics during the 2nd quarter valued at about $46,813,000. FMR LLC bought a new position in shares of G1 Therapeutics during the 2nd quarter valued at about $34,093,000. Franklin Resources Inc. bought a new position in shares of G1 Therapeutics during the 2nd quarter valued at about $10,651,000. Hillhouse Capital Management Ltd. bought a new position in shares of G1 Therapeutics during the 2nd quarter valued at about $7,848,000. Finally, Laurion Capital Management LP bought a new position in shares of G1 Therapeutics during the 2nd quarter valued at about $3,488,000. Institutional investors own 35.10% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This report was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this report on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/10/23/analysts-set-29-67-target-price-for-g1-therapeutics-inc-gthx.html.

About G1 Therapeutics

G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.

Get a free copy of the Zacks research report on G1 Therapeutics (GTHX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for G1 Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.